Posted by Michael Wonder on 02 Aug 2017
Rising prices of targeted oral anti-cancer medications and associated financial burden on Medicare beneficiaries
1 August 2017 - The high cost of oncology drugs threatens the affordability of cancer care.
Previous research identified drivers of price growth of targeted oral anticancer medications (TOAMs) in private insurance plans and projected the impact of closing the coverage gap in Medicare Part D in 2020.
This study examined trends in TOAM prices and patient out-of-pocket (OOP) payments in Medicare Part D and estimated the actual effects on patient OOP payments of partial filling of the coverage gap by 2012.
